Effect of intraluminal administration of amino acids upon plasma glicentin

Ohneda, Akira; Kobayashi, Takashi; Nihei, Jiro; Takahashi, Hitomi

doi:10.1016/s0168-8227(88)80061-5

Cited by 11 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in animal models revealed that glicentin secretion is stimulated by intraluminal administration of glucose, amino acids or fat ingestion. 10–12 These observations were confirmed in humans, where higher postprandial glicentin values were observed compared with the fasting situation in neonates 13,14 and increased values were found following glucose ingestion in adults. 15,16 In addition, it is possible that glicentin could play an indirect role in glycaemic regulation as suggested by reports of an increased insulin secretion 5,6 and decreased glucagon secretion 6,17 after glicentin administration in several animal models.…”

Section: Discussionsupporting

confidence: 53%

Decreased serum glicentin concentration in patients with severe and morbid obesity

Raffort

Panaïa‐Ferrari

Lareyre³

et al. 2017

Ann Clin Biochem

View full text Add to dashboard Cite

Background Proglucagon-derived hormones represent a family of peptides mainly produced in the pancreas and the intestine. While several proglucagon-derived peptides play key roles in metabolic diseases, little is known about glicentin. The aim of the present study was to investigate serum glicentin concentrations in individuals with adult obesity and to study its potential link with various metabolic parameters. Methods Fifty-two individuals with normal body mass index (BMI < 25 kg/m) and 39 patients with severe or morbid obesity (BMI > 35 kg/m) were prospectively included at the University Hospital of Nice between January 2014 and April 2016. Clinical data were recorded, and a fasting blood sample was collected to measure glicentin, glucose, insulin, C-peptide, total cholesterol, triglyceride, LDL and HDL-cholesterol. In addition, a homeostasis model assessment for insulin resistance (HOMA2-IR) was also calculated. Results Patients with severe and morbid obesity had significantly higher plasma glucose, together with higher serum concentrations of insulin, C-peptide, HOMA2-IR, triglyceride, LDL-cholesterol and lower serum concentrations of HDL-cholesterol compared with individuals with a normal body mass index. The obese patients displayed significantly lower fasting serum concentrations of glicentin compared with subjects with a normal body mass index (12 pmol/L vs. 24 pmol/L, P < 0.0001). In the total population, fasting glicentin concentrations did not correlate with BMI, glycaemic parameters (glucose, insulin, C-peptide, HOMA-IR) or lipid parameters (total cholesterol, triglyceride, LDL and HDL-cholesterol). Conclusion To the best of our knowledge, this is the first study reporting serum glicentin concentrations in healthy lean and obese adult subjects. We found that fasting serum glicentin concentrations are decreased in patients with severe or morbid obesity suggesting the potential interest of this peptide in obesity and metabolic-related disorders.

show abstract

Section: Discussionsupporting

confidence: 53%

Decreased serum glicentin concentration in patients with severe and morbid obesity

Raffort

Panaïa‐Ferrari

Lareyre³

et al. 2017

Ann Clin Biochem

View full text Add to dashboard Cite

show abstract

“…We now know glicentin is released post-prandially from Lcells of the distal ileum and colon, particularly in response to glucose, lipids and amino acids, especially arginine, entering the duodenum [ (272)(273)(274); Figure 2]. The hormone elicits a number of physiological effects such as a paracrine role in promoting intestinal growth and regulating motility (275), as well as playing a role in glucose homeostasis through augmenting insulin secretion and inhibiting glucagon secretion (276).…”

Section: Glicentin and Glicentin-related Pancreatic Peptidementioning

confidence: 99%

Proglucagon-Derived Peptides as Therapeutics

et al. 2021

View full text Add to dashboard Cite

Initially discovered as an impurity in insulin preparations, our understanding of the hyperglycaemic hormone glucagon has evolved markedly over subsequent decades. With description of the precursor proglucagon, we now appreciate that glucagon was just the first proglucagon-derived peptide (PGDP) to be characterised. Other bioactive members of the PGDP family include glucagon-like peptides -1 and -2 (GLP-1 and GLP-2), oxyntomodulin (OXM), glicentin and glicentin-related pancreatic peptide (GRPP), with these being produced via tissue-specific processing of proglucagon by the prohormone convertase (PC) enzymes, PC1/3 and PC2. PGDP peptides exert unique physiological effects that influence metabolism and energy regulation, which has witnessed several of them exploited in the form of long-acting, enzymatically resistant analogues for treatment of various pathologies. As such, intramuscular glucagon is well established in rescue of hypoglycaemia, while GLP-2 analogues are indicated in the management of short bowel syndrome. Furthermore, since approval of the first GLP-1 mimetic for the management of Type 2 diabetes mellitus (T2DM) in 2005, GLP-1 therapeutics have become a mainstay of T2DM management due to multifaceted and sustainable improvements in glycaemia, appetite control and weight loss. More recently, longer-acting PGDP therapeutics have been developed, while newfound benefits on cardioprotection, bone health, renal and liver function and cognition have been uncovered. In the present article, we discuss the physiology of PGDP peptides and their therapeutic applications, with a focus on successful design of analogues including dual and triple PGDP receptor agonists currently in clinical development.

show abstract

“…Food intake and ingestion of nutrients including glucose, lipids or amino-acids have been identified to act as stimulating factors for glicentin secretion [21,[27][28][29]. In that context, two main hypotheses previously described by other authors can be proposed and transposed to explain glicentin increase after bariatric surgery: the hindgut and the foregut hypothesis [30,31].…”

Section: Discussionmentioning

confidence: 97%